like growth factor I; growth Severe combined immunodeficiencies (SCIDs) are a genotypically and phenotypically heterogeneous group of disorders characterized by a severe defect of both T-and B-cell immunity. These forms are generally fatal within the first year of life, although a few atypical cases may be characterized by a milder phenotype. In any case, bone marrow transplantation (BMT) is indicated to ensure these patients a long-term survival. We have recently reported a patient affected with X-linked SCID due to an L183S hemizygous missense mutation of the common g chain transducing element, in whom, due to the difficulty in finding an HLA compatible donor, we had the opportunity to observe the longitudinal growth for several years before BMT. 1 We documented a severe short stature due to in vivo impaired insulin-like growth factor-I (IGF-I) production following growth hormone (GH) administration, and an in vitro abnormal protein tyrosine phosphorylation following GH receptor (GH-R) triggering of peripheral blood lymphocytes (PBLs).
1 These data were consistent with a peripheral GH hyporesponsiveness. Peripheral GH insensitivity consists of a heterogeneous group of disorders characterized by short stature, normal or elevated circulating GH levels and low serum concentration of IGF-I and IGF-binding protein-3 (IGFBP-3).
2 A molecular alteration of the GH-R gene or of the GH-R signal transduction machinery has been implicated in a few cases of GH insensitivity. [2] [3] [4] Although IGF-I is also produced in a wide variety of extra hepatic tissues, including human lymphocytes, 5, 6 the major source is considered to be the liver. 7 We now report on the complete normalization of the GH-R/IGF-I axis paralleling a fully competent immunological reconstitution achieved by BMT in a patient with g-SCID and peripheral GH insensitivity.
Case report
The patient presented at 4 months of age with severe hyporegenerative anemia and an immunological SCID phenotype characterized by the absence of T and NK cells, and the presence of non-functional B cells. The mutational analysis of the g chain gene revealed an L183S hemizygous missense mutation responsible for the phenotype of our patient. Since the age of 2 years, a proportionate short stature was noted (Figure 1) . Thereafter, while the patient was waiting for a BMT, a progressive impairment of growth velocity and a marked delay in bone age maturation were observed, despite a successful prophylaxis against infections and an adequate nutritional intake. At the age of 5 years, bone age was 2.5 years and growth velocity was 3 cm/year in the last 2 years (o3rd centile). Endocrine assessment showed normal thyroid and adrenal function, and normal GH secretion after two provocative tests. The basal IGF-I was low and failed to increase after IGF-I generation test. 1 A genetic alteration of the GH-R gene was ruled out by molecular analysis. By contrast, an abnormal pattern of in vitro protein tyrosine phosphorylation following GH-R triggering of PBL was documented, thus indicating a peripheral GH insensitivity. 1 At the age of 5.2 years, a BMT from an unrelated donor mismatched for one A locus was performed, with a conditioning regimen consisting of busulfan (À7 and À6 days), thiotepa (À5 and À4 days), cyclophosphamide (À3 and À2 days) and antilymphocyte globulin (À3 and À2 days). The patient was then treated with prednisone and cyclosporine for 9 and 15 months, respectively, to prevent graft-versus-host disease.
After BMT, hematological reconstitution (Table 1) was promptly achieved, platelet and neutrophil counts being 67.40 Â 10 9 /l and 2.76 Â 10 9 /l, respectively, at þ 1 month. Immunological reconstitution was appreciable soon after BMT. At 7 months after BMT, CD4 þ cells were 228/ml, and by 12 months the appearance of CD4 þ cells of the naı¨ve phenotype and of a normal number of B cells were documented, as illustrated in Table 1 . A fully functional recovery was reached 24 months after BMT, when a normal proliferative response to common mitogens was observed. Growth velocity improved soon after BMT reaching the maximum increment of 13.5 cm/year (497th centile) after the withdrawal of steroid and cyclosporine (Figure 1 ). At the last observation at the age of 8.5 years, his height was 116 cm (o5th centile), his weight was 20 kg (weight/height ratio: 50th centile) and bone age maturation was 6.5 years. Although his stature is still below the normal values for age, it is above his genetic target. At 2 years after BMT, during the catch-up growth period, the GH-R/IGF-I axis was completely restored when compared to pre-BMT (Figure 2 ). The basal IGF-I values after BMT were significantly higher than the pre-BMT values (À0.6 SDS vs À1.2 SDS, respectively). Moreover, short-term in vivo administration of GH induced a significant increase of IGF-I by the 4th day. The percentage of IGF-I increase was 100% after BMT as compared to 29% before BMT. The behavior of IGFBP-3 paralleled that of IGF-I, as expected (data not shown).
Discussion
This case represented a unique opportunity to evaluate the linear growth and the GH-R/IGF-I axis in a patient with g-SCID, since such patients usually undergo BMT in the first year of life. In our patient, the difficulty in finding an HLA matched donor delayed the time of transplantation and gave us the opportunity to follow his growth over a period of time. Several remarks are suggested by the data collected from our patient. As already reported, the g chain gene mutation is associated with a linear growth defect due to abnormalities of GH-R signaling in lymphocytes. 1 Our previous interpretation of this finding was that the g chain was implicated in the GH-R signaling. However, as for the intimate mechanism involved, no definitive explanation is available.
Before BMT, SCID patients may have other potential causes of growth failure, such as chronic inflammation or malabsorption, although these conditions were not present in our patient. However, it is remarkable that, whatever the mechanism involved in the GH-R signaling abnormality in our patient, BMT was able to normalize both serum IGF-I levels and linear growth.
Since the g element shared by several receptors is not a component of the homodimeric GH-R itself, it is possible to hypothesize that some downstream molecules controlled by g may be implicated in GH-R signaling.
Although IGF-I is expressed in a wide variety of tissues, 7 it is produced predominantly by the liver while the lymphocyte-derived contribution is generally considered to be negligible in growth physiology. In spite of the impaired GH-IGF-I axis frequently observed after allogeneic transplantation, 8 in our patient, lymphocyte reconstitution following BMT paralleled a functional restoration of the GH-IGF-I axis, and normalization of linear growth. This observation suggests that cells derived from hematopoietic stem cells exert an unexpectedly significant role in producing both IGF-I and IGFBP-3. Our observation is in keeping with that reported in mice in which the IGF-I gene was exclusively deleted in the liver. 9, 10 These mice displayed a 75% reduction in serum IGF-I levels; however, they had a normal body growth, indicating that extra hepatic sources of IGF-I play a major role.
Our case suggests that the production of IGF-I from hematopoietic stem cell-derived components is important for linear growth. Our observation also implies that stem cell-based therapies may be a potential field of investigation for the correction of genetic disorders of the GH-R/IGF-I axis. 
